Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELA-M-R: Belatacept for Subclinical Antibody Mediated Rejection in Kidney Transplant
NCT06291103Phase 3Not yet recruiting
- Sponsor
- Rouen University Hospital
- Start
- Jul 2026
- Primary completion
- Aug 2032
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of belatacept in kidney transplant rejection (2 arms), sponsored by Rouen University Hospital. Primary endpoint: Efficacy of belatacept combined with standard of care, compared to calcineurin inhibitors (CNI) combined with standard of care at 12 months. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
belatacept
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT06291103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06291103.